Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
3 Investable Laggards In An Overbought Market
05:13pm, Tuesday, 28'th Oct 2025
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)
05:30pm, Tuesday, 23'rd Sep 2025
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 8
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
12:34pm, Thursday, 18'th Sep 2025
On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therap
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders
07:02am, Thursday, 18'th Sep 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the
Roche to buy US biotech 89bio in $3.5bn deal
03:07am, Thursday, 18'th Sep 2025
Roche has agreed to acquire American biotech 89bio in a transaction worth up to $3.5 billion, as it looks to expand its pipeline of treatments for liver and cardiometabolic diseases. The Swiss pharmac
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders
03:02am, Thursday, 18'th Sep 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn
Roche to Buy 89bio for Up to $3.5 Billion
01:29am, Thursday, 18'th Sep 2025
The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity comorbidity.
Roche to acquire liver drug developer 89bio for up to $3.5 billion
01:18am, Thursday, 18'th Sep 2025
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.
89bio, Inc. Announces Agreement to be Acquired by Roche
01:02am, Thursday, 18'th Sep 2025
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
10:09am, Tuesday, 09'th Sep 2025
89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - C
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Sep 2025
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializa
